Invesaro

Stocks Comparison

Inogen vs STERIS: revenue, profit, margins and growth compared

Inogen brought in $348.7M of revenue in fiscal 2025, STERIS $5.9B in fiscal 2026. Revenue changed by +3.9% at Inogen and +8.7% at STERIS on the year before, so STERIS grew faster. Inogen kept -6.5% of its revenue as net profit, STERIS 13.2%. Free cash flow was -$13.7M at Inogen and $972.4M at STERIS.

Side by side, latest fiscal year

INGNSTE
Fiscal year endedFY2025 (December 31, 2025)FY2026 (March 31, 2026)
Revenue$348.7M$5.9B
Revenue growth+3.9%+8.7%
Net income-$22.7M$782.3M
Net margin-6.5%13.2%
Free cash flow-$13.7M$972.4M
Free cash flow margin-3.9%16.4%
Earnings per share (diluted)-$0.86$7.93
Cash$103.7M$439.6M
Debtn/a$1.8B
Price to earningsn/a26.4
Market value$142.2M$20.4B
Dividend yieldn/a1.18%
Rank by revenue in sector#213 of 523 · Health care#55 of 523 · Health care

Over the years

Revenue
INGN FY2018: $358.1MINGN FY2019: $361.9MINGN FY2020: $308.5MINGN FY2021: $358MINGN FY2022: $377.2MINGN FY2023: $315.7MINGN FY2024: $335.7MINGN FY2025: $348.7MSTE FY2019: $2.8BSTE FY2020: $3BSTE FY2021: $3.1BSTE FY2022: $4.2BSTE FY2023: $4.5BSTE FY2024: $5.1BSTE FY2025: $5.5BSTE FY2026: $5.9BFY18FY19FY20FY21FY22FY23FY24FY25FY26
INGN $348.7MSTE $5.9B
Net income
INGN FY2018: $51.8MINGN FY2019: $21MINGN FY2020: -$5.8MINGN FY2021: -$6.3MINGN FY2022: -$83.8MINGN FY2023: -$102.4MINGN FY2024: -$35.9MINGN FY2025: -$22.7MSTE FY2019: $303.7MSTE FY2020: $407.7MSTE FY2021: $397.4MSTE FY2022: $243.9MSTE FY2023: $107MSTE FY2024: $378.2MSTE FY2025: $614.6MSTE FY2026: $782.3MFY18FY19FY20FY21FY22FY23FY24FY25FY26
INGN -$22.7MSTE $782.3M
Net margin
INGN FY2018: 14.5%INGN FY2019: 5.8%INGN FY2020: -1.9%INGN FY2021: -1.8%INGN FY2022: -22.2%INGN FY2023: -32.5%INGN FY2024: -10.7%INGN FY2025: -6.5%STE FY2019: 10.9%STE FY2020: 13.5%STE FY2021: 12.8%STE FY2022: 5.8%STE FY2023: 2.4%STE FY2024: 7.4%STE FY2025: 11.3%STE FY2026: 13.2%FY18FY19FY20FY21FY22FY23FY24FY25FY26
INGN -6.5%STE 13.2%
Revenue growth
INGN FY2019: +1.1%INGN FY2020: -14.8%INGN FY2021: +16.1%INGN FY2022: +5.4%INGN FY2023: -16.3%INGN FY2024: +6.4%INGN FY2025: +3.9%STE FY2020: +8.9%STE FY2021: +2.5%STE FY2022: +35.9%STE FY2023: +7.4%STE FY2024: +13.3%STE FY2025: +6.2%STE FY2026: +8.7%FY19FY20FY21FY22FY23FY24FY25FY26
INGN +3.9%STE +8.7%
Free cash flow
INGN FY2018: $51.9MINGN FY2019: $37.5MINGN FY2020: $32.6MINGN FY2021: $18.2MINGN FY2022: -$40.9MINGN FY2023: -$8.5MINGN FY2024: $2.6MINGN FY2025: -$13.7MSTE FY2019: $349.8MSTE FY2020: $376MSTE FY2021: $450.4MSTE FY2022: $397.2MSTE FY2023: $395MSTE FY2024: $613MSTE FY2025: $778MSTE FY2026: $972.4MFY18FY19FY20FY21FY22FY23FY24FY25FY26
INGN -$13.7MSTE $972.4M

Fiscal years as each company reports them; the two may end in different months.

Questions about Inogen and STERIS

Which is bigger by revenue, Inogen or STERIS?

STERIS is bigger by revenue: $5.9B in fiscal 2026, against $348.7M for Inogen in fiscal 2025.

Which keeps more of its revenue as profit, Inogen or STERIS?

Inogen had a net margin of -6.5% in fiscal 2025; STERIS had 13.2% in fiscal 2026.

Which grew revenue faster, Inogen or STERIS?

In their latest fiscal years revenue changed by +3.9% at Inogen and +8.7% at STERIS.

Where do these numbers come from?

From the annual reports each company files with the SEC (10-K, or 20-F and 40-F for foreign companies), read from their XBRL data. Margins and growth are simple arithmetic on those figures. Nothing here is a recommendation.

More comparisons

Compare more companies